New York, NY -- November 30, 2020 -- InvestorsHub NewsWire -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues a new research report.

As reported on November 11, 2020, HUMBL, LLC is merging with Tesoro Enterprises, Inc. (OTCPINK: TSNP). Singapore-based Cyberbeat, a leading digital payments and financial technologies company led by veteran digital payment industry executives of the Asia Pacific region has made a strategic investment into HUMBL, LLC. The cash investment is consummate with a new partnership in which Cyberbeat gains the non-exclusive rights to sell, distribute and deploy HUMBL and HUMBL Hubs technologies into key verticals in the Asia Pacific in calendar year 2021 and beyond.
Tesoro announced recently that the company’s CEO and President, Brian Foote, has agreed to convert over 318 million shares recently purchased by him out of the retail market to a new class of Preferred shares.

Enzolytics, Inc. (OTCPINK: ENZC) is negotiating a merger with BioClonetics Immunotherapeutics, Inc. The clinical goal of the merger is to test in combination the Enzolytics ITV-1 peptide in conjunction with BioClonetics anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. BioClonetics also has applications pending with the National Institute of Health (NIH) and the National Science Foundation (NSF) for further development of our anti-HIV monoclonal antibodies and our proposed production of anti-SARS-CoV-2 (Coronavirus) antibodies.

See the full report for info on our potential home run stock READ MORE
Copy and paste to browser may be required

In early October, Northwest Biotherapeutics, Inc. (OTCQB: NWBO) announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked. The company either does not yet know or has not yet released the results. They are hopeful that DCVax®-L can become an important new treatment option for patients who urgently need more and better treatments for Glioblastoma brain cancer. The clinical trial for DCVax-L has been going on for over a decade so the outcome has been widely anticipated. A positive data release could be a major catalyst for NWBO shares.

Sycamore Entertainment Group, Inc. (OTCPINK: SEGI) has acquired the rights to author Tony McAleer’s film, IN DARKNESS & IN LIGHT: A Journey of Atonement in Auschwitz. McAleer is a former holocaust denier and a founding member of the anti-hate activist group Life After Hate and he takes us on a deeply personal journey with his film as he fulfills a promise he made on the road to healing from hate. Sycamore plans to debut the film in February 2021 at The Monaco International Film Festival followed by a North American release in March of 2021.

Our full comprehensive report is available with no obligation READ MORE
Copy and paste to browser may be required –

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering mid, small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is defined on pages, landing pages where a ticker that we have been compensated to mention appears.

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, or “expert” for further information on analyst credentials, please email TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Traders News Source

Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Northwest Biotherapeutics (QB) Charts.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Northwest Biotherapeutics (QB) Charts.